Register Login
Register to leave comments
  • News bot Jan. 9, 2026, 10:04 p.m.

    🔍 TAYMANS JILL M (Executive)

    Company: CRYO CELL INTERNATIONAL INC (CCEL)

    Report Date: 2026-01-07

    Transaction Summary:

    • Total transactions: 8
    • Derivative instruments: 7
    • Holdings reported: 6
    • Total shares acquired: 30,000
    • Total shares held: 99,896

    Detailed Transactions and Holdings:

    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-01-07 | Code: H | shares_owned_after: 45,396.00
    • Acquired 10,000 shares of Stock Option at $3.54 per share (Derivative)
      Date: 2026-01-07 | Code: A | Expires: 2031-01-07 | Exercise: 2026-01-07 | equity_swap_involved: false | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F4
    • Acquired 20,000 shares of Stock Option at $3.54 per share (Derivative)
      Date: 2026-01-07 | Code: A | Expires: 2031-01-07 | Exercise: 2026-01-07 | equity_swap_involved: false | shares_owned_after: 20,000.00 | transaction_form_type: 4 | Footnotes: F5
    • Holds 7,500 shares of Stock Option at $3.1 per share (Derivative)
      Date: 2026-01-07 | Code: H | Expires: 2026-06-02 | Exercise: 2019-06-02 | shares_owned_after: 7,500.00
    • Holds 7,000 shares of Stock Option at $8.0 per share (Derivative)
      Date: 2026-01-07 | Code: H | Expires: 2027-09-23 | Exercise: 2020-09-23 | shares_owned_after: 7,000.00 | Footnotes: F1
    • Holds 20,000 shares of Stock Option at $4.62 per share (Derivative)
      Date: 2026-01-07 | Code: H | Expires: 2028-01-13 | Exercise: 2023-01-13 | shares_owned_after: 20,000.00
    • Holds 10,000 shares of Stock Option at $5.88 per share (Derivative)
      Date: 2026-01-07 | Code: H | Expires: 2028-12-22 | Exercise: 2023-12-22 | shares_owned_after: 10,000.00 | Footnotes: F2
    • Holds 10,000 shares of Stock Option at $7.35 per share (Derivative)
      Date: 2026-01-07 | Code: H | Expires: 2030-01-21 | Exercise: 2025-01-21 | shares_owned_after: 10,000.00 | Footnotes: F3

    Footnotes:

    • F1: Stock options vest 1/5 per year commencing on September 23, 2020.
    • F2: Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
    • F3: Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.
    • F4: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.
    • F5: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

Search

News categories